The collaborators have been awarded £800,000 of Innovate UK Biomedical Catalyst funding to develop an integrated and scalable platform to manufacture allogeneic induced pluripotent stem cell (iPSC) derived immunotherapies. The project consortium is led by Plasticell, a biotechnology company developing next-generation stem cell technologies and advanced therapies. The team additionally comprises the Cell and Gene Therapy Catapult (CGT Catapult), an [...]

Plasticell Ltd, a developer of stem cell technologies and advanced therapies, has announced today that it has entered into a strategic collaboration with Singapore-based LambdaGen. Together, the two companies will exploit genome editing technologies based on synthetic lambda integrases that allow specific insertion of large gene cassettes into the human genome The UK-Singapore partnership is in part financed by a [...]

Plasticell, the biotechnology company specialising in cell and gene therapy research, has completed an equity financing round raising a total of £1.4 million. Plasticell specialises in using massively parallel screening technologies to discover, develop and optimise manufacturing of high value cell therapies derived from stem cells. Its award-winning combinatorial screening technology, CombiCult®, can be applied to any cell culture process [...]

Plasticell Ltd, a developer of stem cell technologies and regenerative medicines, has announced that the Advanced Stem Cell Training Network (ASCTN), a European research consortium in which the company is a partner organisation, has successfully bid for over €3,700,000 in funding from the European Union to create and exploit advanced cellular models of neurological disorders – notably Parkinson's, Huntington's and [...]

Plasticell, a developer of stem cell technologies and regenerative medicines, has announced that it has been contracted by the Ministry of Defence (MoD) in a pilot programme to develop regenerative medicines for the treatment of injuries resulting from combat or terrorism. Plasticell will deploy its combinatorial stem cell screening platform, CombiCult®, to develop technologies for the conversion of pluripotent stem [...]

UK’s innovation agency provides funding to develop advanced technologies for the manufacturing of autologous ex vivo gene therapies. Plasticell, a developer of stem cell technologies and therapies, has announced it is leading a consortium of pioneering gene therapy groups at UCL Great Ormond Street Institute of Child Health (ICH) to develop advanced technologies for the manufacturing of ex vivo gene [...]

Plasticell, a developer of innovative stem cell technologies and cell therapies, today announced it will collaborate with Anthony Nolan, a leading research organisation dedicated to saving the lives of people with blood cancers, to progress clinical development of Plasticell’s ex vivo expanded cord blood-derived hematopoietic stem cell product. Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative therapy for patients [...]

Plasticell, the biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem cell screening technology, CombiCult®, to optimise the directed differentiation of induced pluripotent stem cells (iPSCs) to specific blood cell lineages for use by GSK in its therapeutic research. In the collaboration, Plasticell will use its [...]

Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, today announced it has partnered with Kings College London to progress preclinical trials of its artificial blood platelet product, manufactured from pluripotent stem cells. The work is supported by a MedCity research grant which funds collaboration between leading SMEs and academics from London universities. Over 10 million units of [...]